Analyst Coverage
| Firm | Analyst |
|---|---|
| Barclays Capital | Rich Silver |
| BofA Merrill Lynch | Gregg Gilbert |
| Cowen | Ian Sanderson |
| Caris & Company | Jim Molloy |
| Deutsche Bank | David Steinberg |
| Lazard Capital Markets | Bill Tanner |
| Oppenheimer | John Newman |
| Roth Capital Partners | Scott Henry |
| SunTrust Robinson Humphrey | Frank Pinkerton |
| Thomas Weisel Partners | Annabel Samimy |
Eurand Pharmaceuticals is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Eurand Pharmaceuticals's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Eurand Pharmaceuticals or its management. Eurand Pharmaceuticals does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Stock Information
| Ticker | EURX |
| Exchange | NASDAQ |
| Price | $9.25 |
| Change | - 0.08 |
| Volume | 33,000 |
| Sep 7, 2010 - 3:59 PM ET | |
Shareholder Tools
Eurand Fact Sheet PDF